An observational study in Healthy Volunteer, sponsored by Azienda Ospedaliero-Universitaria di Parma. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-14.
Sponsored by Azienda Ospedaliero-Universitaria di Parma · Observational
Experimental, drug-free, longitudinal, single-centre study for the prediction of cardiometabolic risk in Barilla Off-Spring Study subjects by analysing the evolution of transcriptomic signatures
In Westernized societies, common metabolic and cardiovascular diseases have complex etiologies involving dynamic genome-metagenome-environment interactions. The early molecular alterations that initiate and sustain their progression, although still only partially understood, are thought to share common roots in the terrain of insulin resistance (IR). In recent decades, reciprocal relationships between IR and inflammation have been unraveled, leading to the general concept of "meta-inflammation". In turn, the regulatory role played by metabolic signatures in immune cells has led to the concept of "immunometabolism". In particular, in these meta-inflammation-related disorders, there is a paucity of prospective gene expression data, especially in the early stages of their natural history. Gene expression profiling of peripheral blood mononuclear cells (PBMCs) may be a useful and accessible window into the pathophysiology of processes occurring in difficult-to-access organs and tissues. In a deeply phenotyped healthy cohort, the Barilla Offspring Study, a transcriptomic signature exclusively associated with IR was found by analyzing PBMC gene expression with a novel rank-based classification method, which was also found to discriminate diseased from healthy individuals in Alzheimer's disease, chronic heart failure and type 2 diabetes. The granularity of this approach can be further improved by examining gene expression in monocytes, as cells of innate immunity and mainly implicated in inflammatory/degenerative disorders and their risk factors. In this longitudinal study, we aim to identify the transcriptomic signature(s) in circulating immune cells and inflammatory biomarkers that predict or are associated with 15-year changes in glucose tolerance and/or carotid artery atherogenic phenotype. The study has solid premises: i. The cohort of subjects offers a unique opportunity to identify PBMC transcriptomic trajectories (baseline and 15-year follow-up) that predict changes in cardiometabolic phenotype; ii. cross-sectional assessment of monocyte transcriptomic profiling in the same cohort may uncover additional lineage-specific signatures associated with different cardio-metabotypes at follow-up, allowing comparison with PBMC; iii. an innovative rank-based classification method - SCUDO and its extensions - will be used, in addition to standard methods, to compute transcriptomic analyses. The results of the study may identify cellular transcriptomic signatures and trajectories, which could link cardiometabolic phenotypes at the molecular and cellular level, highlighting possible biological mechanisms of cardiometabolic disease susceptibility and progression, and unveiling a wide range of molecular targets in PBMC and, especially, monocytes, which can be further investigated for their validity as peripheral biomarkers for risk assessment. The findings will also provide new insights into targeted pharmacological strategies for the prevention and/or treatment of cardiometabolic diseases.
Azienda Ospedaliero-Universitaria di Parma is the lead sponsor of 43 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
healthy adults who participated in the cross-sectional Barilla Offspring Study in 2006-2007
Exclusion Criteria:
Other: Evaluation of transcriptomic and cardio-metabolic profiles
The parameters and variables collected in 2006-2007 (T0) will be re-evaluated at the follow-up visit (T1), including demographic, anthropometric, lifestyle data (smoking habit, physical activity, sleep quality) blood pressure, standard biochemical analysis and inflammatory profile. To assess the evolution of glucose tolerance and vascular damage, metabolic (OGTT) and cardiovascular (carotid ecodoppler) profile analyses will be repeated. For gene expression analyses, in addition to messenger RNA from PBMCs (as at T0), RNA from PBMC-derived monocytes will also be extracted and sequenced at T1.
Selection of a set of candidate genes directly correlated with the development of altered metabolic phenotypes
All data related to the transcriptomics of PBMCs at T0 (2006-2007) will be retrieved. At T1, a blood sample will be collected from which PBMCs will be isolated. Total RNA will be purified and its quality tested using the Quibit fluorimetric technique and the Tape-station system. From the same blood sample, the monocyte subpopulation will also be isolated and used to identify the specific transcriptomic signature. Both RNA datasets, collected at T0 and T1, will be processed to identify informative transcriptomic signatures of baseline and follow-up conditions. The sets will be converted to obtain a profile for a symbol gene; this will allow easier comparison of the calculated transcriptomic signatures between different datasets, facilitating the biological interpretation of the results.
Time frame: within six months of the enrolment visit
Selection of a set of candidate genes directly related to the development of altered vascular phenotypes
All data related to the transcriptomics of PBMCs at T0 (2006-2007) will be retrieved. At T1, a blood sample will be collected from which PBMCs will be isolated. Total RNA will be purified and its quality tested using the Quibit fluorimetric technique and the Tape-station system. From the same blood sample, the monocyte subpopulation will also be isolated and used to identify the specific transcriptomic signature. Both RNA datasets, collected at T0 and T1, will be processed to identify informative transcriptomic signatures of baseline and follow-up conditions. The sets will be converted to obtain a profile for a symbol gene; this will allow easier comparison of the calculated transcriptomic signatures between different datasets, facilitating the biological interpretation of the results.
Time frame: within six months of the enrolment visit
Selection of a set of candidate genes directly related to overt altered metabolic and/or vascular phenotypes.
All data related to the transcriptomics of PBMCs at T0 (2006-2007) will be retrieved. At T1, a blood sample will be collected from which PBMCs will be isolated. Total RNA will be purified and its quality tested using the Quibit fluorimetric technique and the Tape-station system. From the same blood sample, the monocyte subpopulation will also be isolated and used to identify the specific transcriptomic signature. Both RNA datasets, collected at T0 and T1, will be processed to identify informative transcriptomic signatures of baseline and follow-up conditions. The sets will be converted to obtain a profile for a symbol gene; this will allow easier comparison of the calculated transcriptomic signatures between different datasets, facilitating the biological interpretation of the results.
Time frame: within six months of the enrolment visit
Selection of markers directly related to the development of altered metabolic and/or vascular phenotypes.
All data related to the transcriptomics of PBMCs at T0 (2006-2007) will be retrieved. At T1, a blood sample will be collected from which PBMCs will be isolated. Total RNA will be purified and its quality tested using the Quibit fluorimetric technique and the Tape-station system. From the same blood sample, the monocyte subpopulation will also be isolated and used to identify the specific transcriptomic signature. Both RNA datasets, collected at T0 and T1, will be processed to identify informative transcriptomic signatures of baseline and follow-up conditions. The sets will be converted to obtain a profile for a symbol gene; this will allow easier comparison of the calculated transcriptomic signatures between different datasets, facilitating the biological interpretation of the results.
Time frame: within six months of the enrolment visit
Selection of a set of candidate genes directly related to alterations in biohumoral parameters and the inflammatory profile.
All data related to the transcriptomics of PBMCs at T0 (2006-2007) will be retrieved. At T1, a blood sample will be collected from which PBMCs will be isolated. Total RNA will be purified and its quality tested using the Quibit fluorimetric technique and the Tape-station system. From the same blood sample, the monocyte subpopulation will also be isolated and used to identify the specific transcriptomic signature. Both RNA datasets, collected at T0 and T1, will be processed to identify informative transcriptomic signatures of baseline and follow-up conditions. The sets will be converted to obtain a profile for a symbol gene; this will allow easier comparison of the calculated transcriptomic signatures between different datasets, facilitating the biological interpretation of the results.
Time frame: within six months of the enrolment visit
Selection of a set of candidate genes directly related to alterations in lifestyle.
All data related to the transcriptomics of PBMCs at T0 (2006-2007) will be retrieved. At T1, a blood sample will be collected from which PBMCs will be isolated. Total RNA will be purified and its quality tested using the Quibit fluorimetric technique and the Tape-station system. From the same blood sample, the monocyte subpopulation will also be isolated and used to identify the specific transcriptomic signature. Both RNA datasets, collected at T0 and T1, will be processed to identify informative transcriptomic signatures of baseline and follow-up conditions. The sets will be converted to obtain a profile for a symbol gene; this will allow easier comparison of the calculated transcriptomic signatures between different datasets, facilitating the biological interpretation of the results.
Time frame: within six months of the enrolment visit
This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda Ospedaliero-Universitaria di Parma